ATE306263T1 - Zusammensetzungen zur verabreichung eines cyclooxygenase-2-hemmers an tiere - Google Patents

Zusammensetzungen zur verabreichung eines cyclooxygenase-2-hemmers an tiere

Info

Publication number
ATE306263T1
ATE306263T1 AT00916179T AT00916179T ATE306263T1 AT E306263 T1 ATE306263 T1 AT E306263T1 AT 00916179 T AT00916179 T AT 00916179T AT 00916179 T AT00916179 T AT 00916179T AT E306263 T1 ATE306263 T1 AT E306263T1
Authority
AT
Austria
Prior art keywords
cyclooxygenase
inhibitor
administration
compositions
animals
Prior art date
Application number
AT00916179T
Other languages
English (en)
Inventor
J Timothy Keane
Joseph R Schuh
Alan L Scrivner
Original Assignee
Searle Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22409943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE306263(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Searle Llc filed Critical Searle Llc
Application granted granted Critical
Publication of ATE306263T1 publication Critical patent/ATE306263T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00916179T 1999-03-10 2000-03-09 Zusammensetzungen zur verabreichung eines cyclooxygenase-2-hemmers an tiere ATE306263T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12364499P 1999-03-10 1999-03-10
PCT/US2000/006097 WO2000053149A2 (en) 1999-03-10 2000-03-09 Method and composition for administering a cyclooxygenase-2 inhibitor

Publications (1)

Publication Number Publication Date
ATE306263T1 true ATE306263T1 (de) 2005-10-15

Family

ID=22409943

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00916179T ATE306263T1 (de) 1999-03-10 2000-03-09 Zusammensetzungen zur verabreichung eines cyclooxygenase-2-hemmers an tiere

Country Status (9)

Country Link
EP (2) EP1637137A3 (de)
JP (1) JP2002538189A (de)
AT (1) ATE306263T1 (de)
AU (1) AU778538B2 (de)
CA (1) CA2363590A1 (de)
DE (1) DE60023119T2 (de)
ES (1) ES2249253T3 (de)
NZ (1) NZ513965A (de)
WO (1) WO2000053149A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20010582A2 (en) * 1999-12-08 2002-08-31 Pharmacia Corp Valdecoxib compositions
CO5261556A1 (es) * 1999-12-08 2003-03-31 Pharmacia Corp Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico
KR100717549B1 (ko) * 1999-12-22 2007-05-11 파마시아 코포레이션 시클로옥시게나제-2 억제제의 이중-방출 조성물
US20020009421A1 (en) * 2000-06-01 2002-01-24 Wilder Karol J. Therapy following skin injury from exposure to ultraviolet radiation
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
KR20070120617A (ko) 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
EP1429756B1 (de) 2001-09-21 2006-11-22 Schering Corporation Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
CN1659131A (zh) 2002-04-08 2005-08-24 葛兰素集团有限公司 2－((2－烷氧基)－苯基)－环戊－1－烯基)芳香碳－以及杂环羧酸及其衍生物
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
CA2504916A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
PT1534305E (pt) 2003-05-07 2007-02-28 Osteologix As Tratamento de afecções cartilagineas / osseas com sais de estroncio hidrosoluveis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585504A (en) * 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
CA2223154A1 (en) * 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
ATE211918T1 (de) * 1996-10-21 2002-02-15 Morten Sloth Weidner Pharmazeutische zusammenstellungen mit parthenium integrifolium oder mit einem extrakt oder einer komponente davon, verwendung dieses pflanzenmaterials zur herstellung von medizin und ein verfahren zur extraktherstellung von parthenium integrifolium
AU730211B2 (en) * 1996-11-19 2001-03-01 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
DZ2479A1 (fr) * 1997-05-05 2003-02-01 Pfizer Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
EP1158977B1 (de) 2005-10-12
WO2000053149A3 (en) 2000-12-28
NZ513965A (en) 2004-04-30
EP1637137A2 (de) 2006-03-22
CA2363590A1 (en) 2000-09-14
EP1158977A2 (de) 2001-12-05
AU778538B2 (en) 2004-12-09
EP1158977A4 (de) 2003-09-03
EP1637137A3 (de) 2006-07-05
ES2249253T3 (es) 2006-04-01
AU3732600A (en) 2000-09-28
WO2000053149A2 (en) 2000-09-14
JP2002538189A (ja) 2002-11-12
DE60023119D1 (de) 2006-02-23
DE60023119T2 (de) 2006-07-20

Similar Documents

Publication Publication Date Title
DE60023119D1 (de) Zusammensetzungen zur verabreichung eines cyclooxygenase-2-hemmers an tiere
EP1619960A4 (de) Futtermittelformulierung für land- und wasserbewohner
DE69909298D1 (de) Verfahren zur herstellung einer zusammensetzung zum schutz eines fleischfressenden haustieres gegen krankheiten des abnormalen kohlenhydrat-metabolismus
MY109928A (en) Fatty acid treatment
NZ519980A (en) Pet food composition for treating helicobacter species in pets
ATE323480T1 (de) Zusammensetzungen, enthaltend pinolensäure sowie deren verwendung zur gesundheitserhaltung
BR9507099A (pt) Forma de dosagem método de esterilização composição esterilizante e suplemento alimentar animal compreendendo nitrito acidificado como um agente anti-microbiano
WO2006002976A3 (en) Canine osteoarthritis diet formulation
PL1841743T3 (pl) Amidy kwasu 3-arylo-3-hydroksy-2-aminopropionowego, amidy kwasu 3-heteroarylo-3-hydroksy-2-aminopropionowego i powiązane związki o działaniu przeciwbólowym i/lub immunostymulacyjnym
UA90719C2 (ru) Способ изготовления молока или молочных продуктов с высоким содержанием мелатонина
NZ512086A (en) Method of increasing fat firmness and improving meat quality in animals
ATE258435T1 (de) Pinolensäure gegen diabetes
MX2007001931A (es) Aditivo alimentario.
EP1550443A4 (de) Zusammensetzung gegen stressbedingte erkrankungen
WO2008075333A3 (en) Edible compositions for preventing hair loss
PT1233678E (pt) Formulacoes zootecnicas que compreendem acidos biliares
ATE355741T1 (de) Verfahren zur herstellung von nährstoffen, nährstoffe und verfahren zur abgabe von nährstoffen
ATE385175T1 (de) Hemmung von tyrophagus putrescentiae in tierfuttermitteln
EE200300405A (et) Meetod loomasööda lisandina kasutatava D-pantoteenhappe ja/või tema soolade saamiseks
ATE323423T1 (de) Futter welches die nahrungsaufnahme pro zeiteinheit bei hunden verzögert
MX2021015590A (es) Metodos y composiciones con beneficios renales para felinos.
JP2003246728A5 (de)
WO2002038103A3 (en) Probiotic compositions and methods against bacterial infection in livestock animals
UA34330A (uk) Кормова добавка для птиці
EP1163903A3 (de) Methanal - Injektion zur Behandlung epidemischer Tierkrankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties